All information below describes the compound's chemical identity, laboratory handling, and the published research literature. It describes molecular targets and results in laboratory and animal models only — not effects in humans — and is not evidence of any human benefit.
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its primary sequence is built on the native GIP peptide backbone and incorporates two non-coded 2-aminoisobutyric acid (Aib) residues together with a C20 fatty diacid moiety conjugated through a linker to a lysine side chain — structural modifications reported in the literature to be associated with resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, albumin binding, and a prolonged circulating half-life relative to native incretin peptides.
It does not occur freely in nature; it is a chemically synthesized analogue characterized in receptor-pharmacology and metabolic model systems. It is supplied as a reference compound for in vitro and animal research use only. The sections below summarize its chemical identity, laboratory handling, the molecular targets and model systems examined in the published literature, and the primary references — without describing outcomes, efficacy, or effects in humans.
Research Targets & Pathways
Published literature has examined tirzepatide in relation to several molecular systems. These are pathway associations reported in laboratory, animal, and clinical-pharmacology model systems; refer to the cited studies for methods and findings.
- GIP receptor (GIPR) — a class B G protein-coupled receptor; examined in receptor-binding and functional signaling assays.
- GLP-1 receptor (GLP-1R) — a class B G protein-coupled receptor; examined in receptor-binding and functional signaling assays.
- cAMP / protein kinase A signaling — studied in cAMP accumulation assays downstream of GIPR and GLP-1R activation.
- β-arrestin recruitment — characterized in signaling-bias assays comparing the two receptor systems.
- Pancreatic β-cell insulin-secretion pathways — investigated in islet and β-cell model systems.
Model Systems Studied
Tirzepatide has been used as a test compound across a range of published model systems, from recombinant receptor assays to rodent studies and large clinical trial programs. Refer to the cited literature for study designs, endpoints, and findings.
- In vitro receptor pharmacology — HEK293 and related cell lines expressing recombinant human GIPR and GLP-1R; cAMP accumulation and β-arrestin recruitment assays.
- Cellular / islet models — pancreatic β-cell and islet insulin-secretion assay systems.
- Rodent metabolic models — diet-induced obese mouse and rat models used in metabolic pharmacology.
- Clinical trial programs — the SURPASS and SURMOUNT Phase II/III programs, in which glycemic, body-weight, and cardiometabolic endpoints were measured.
Note: much of the published tirzepatide data derives from clinical trial programs sponsored by its originator; independent preclinical replication in isolated model systems is ongoing.
Stability
Tirzepatide's structural modifications — the two Aib substitutions and the C20 fatty-acid acylation — are reported in the literature to confer resistance to DPP-4 cleavage and to mediate albumin binding, physicochemical properties relevant to formulation and handling in research settings. It is supplied as a lyophilized powder and handled under standard peptide storage conditions; as with other acylated peptides, mechanical agitation is avoided during reconstitution to preserve structural integrity.
Molecular & Technical Profile
C225H348N48O68 | MW ~4813.5 g/mol | CAS 2023788-19-2 | 39-residue synthetic peptide, dual GIP/GLP-1 receptor agonist
Storage, Reconstitution & Working Concentrations
Storage, reconstitution, and working-concentration values are general laboratory guidance for in vitro and animal research; always confirm against the lot-specific Certificate of Analysis. Molecular weight is reported as an approximate average mass for the acylated peptide.
Current Research Status
Tirzepatide is the active pharmaceutical ingredient in approved prescription drug products marketed as Mounjaro and Zepbound in various jurisdictions. The material supplied by Explicit Research is research-grade tirzepatide intended for in vitro and animal laboratory research only; it is not the approved drug product and is not for human or clinical use. The published evidence base spans in vitro receptor pharmacology, rodent metabolic models, and large clinical trial programs (SURPASS and SURMOUNT). Ongoing research continues to characterize the compound's dual-receptor signaling profile and its behavior across experimental model systems.
Research FAQ
Is tirzepatide approved for human use?
Tirzepatide is the active ingredient in approved prescription drug products (marketed as Mounjaro and Zepbound) in various jurisdictions. The material supplied by Explicit Research, however, is research-grade tirzepatide for laboratory research use only — it is not the approved drug product and is not for human consumption.
What is tirzepatide's molecular formula and structure?
A synthetic 39-amino-acid peptide and dual GIP/GLP-1 receptor agonist — molecular formula C225H348N48O68, MW ~4813.5 g/mol, CAS 2023788-19-2. It carries two non-coded Aib residues and a C20 fatty diacid moiety linked to a lysine side chain.
How is tirzepatide stored and reconstituted?
Store lyophilized at −20°C, desiccated and protected from light. Reconstitute in sterile or bacteriostatic water or PBS (pH 7.4); store the reconstituted solution at 2–8°C for up to ~28 days and avoid repeated freeze–thaw.
What molecular targets has tirzepatide been studied for?
It has been characterized as a dual agonist at the GIP and GLP-1 receptors (both class B GPCRs), examined in cAMP accumulation and β-arrestin recruitment assays in vitro and across rodent metabolic models and clinical trial programs.
Selected References
- Coskun T, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18:3–14.
- Willard FS, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17):e140532.
- Rosenstock J, et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295):143–155.
- Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 385(6):503–515.
- Del Prato S, et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10313):1811–1824.
- Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 387(3):205–216.